Taiwan approves Japan-based Shionogi's influenza drug for paediatric use
Singapore, April 17 -- Japanese pharma behemoth Shionogi & Co. has announced that its group company Taiwan Shionogi has received approval of a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment and postexposure prophylaxis for influenza virus infection for paediatrics aged 5 to = 12 years of age for treating influenza A or B virus acute infection and the postexposure prophylaxis of influenza in Taiwan. The newly approved indication extends the option for treating and preventing influenza virus infections to children aged 5 to 20 kg, offering a new choice for managing influenza.
Xofluza is a first-in-class, single-dose oral medicine with an innovative mechanism of action that has demonstrated effi...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.